Skip to main content

Advertisement

SpringerLink
Log in

A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

We conducted a phase I study for adjuvant chemotherapy of gemcitabine (GEM) plus S-1 in order to determine the maximum tolerated dose and the recommended dose (RD) and to evaluate the efficacy and toxicity of the regimen in curatively resected patients with biliary cancer.

Methods

The study included 34 patients with adequate organ functions, Eastern Cooperative Oncology Group PS 0-1, under 80 years of age, who had curative resection after August, 2007. Patients received GEM on day 1 and day 15, and S-1 from day 1 to day 14. Dose-limiting toxicities were determined during first two treatment cycles. After determining RD, a feasibility study was continued in the following four treatment cycles.

Results

Hematological toxicity, particularly neutropenia and thrombocytopenia, was the most pronounced toxic effect of gemcitabine and S-1 adjuvant combination chemotherapy. The RD after pancreatoduodenectomy is GEM 1,000 mg/m2 + S-1 80 mg/m2, and RD after hemihepatectomy is GEM 800 mg/m2 + S-1 60 mg/m2.

Conclusions

The pharmacokinetics of GEM and S-1 indicate that changing the dose of adjuvant chemotherapy based on the operation method for biliary cancers is reasonable. We believe that this regimen will be established as an effective adjuvant chemotherapy for biliary cancer in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sobin LH, Wittekind CH (eds) (2002) UICC TNM Classification of malignant tumors. Liver. 6th edn. Wiley-Liss, New York, pp 81–92

  2. De Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. New Engl J Med 341:1368–1378

    Article  PubMed  Google Scholar 

  3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96

    Article  PubMed  Google Scholar 

  4. Okusaka T (2002) Chemotherapy for biliary tract cancer in Japan. Semin Oncol 29:51–53

    PubMed  CAS  Google Scholar 

  5. Patel T (2002) Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2:10

    Article  PubMed  Google Scholar 

  6. Shaib Y, El-Serag HB (2004) The epidemiology of cholangiocrcinoma. Semin Liver Dis 24:115–125

    Article  PubMed  Google Scholar 

  7. National Cancer Center (2007) Cancer statistics in Japan. http://www.fpcr.or.jp/publivation/statistics.html

  8. Jarnagin WR, Fong Y, De Matteo RP, Gonen M, Burke EC, Bodniewicz BSJ, Youssef BAM, Klimstra D, Blumgart LH (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234:507–517

    Article  PubMed  CAS  Google Scholar 

  9. Nimura Y, Kamiya J, Kondo S, Nagino M, Uesaka K, Oda K, Sano T, Yamamoto H, Hayakawa N (2000) Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg 7:155–162

    Article  PubMed  CAS  Google Scholar 

  10. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T; Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95:1685–1695

    Google Scholar 

  11. Nakeeb A, Tran KQ, Black MJ, Erickson BA, Ritch PS, Quebbeman EJ, Wilson SD, Demeure MJ, Rilling WS, Dua KS, Pitt HA (2002) Improved survival in resected biliary malignancies. Surgery 132:555–564

    Article  PubMed  Google Scholar 

  12. Nelson JW, Ghofoori AP, Willett CG, Tyler DS, Pappas TN, Clary BM, Hurwitz HI, Bendell JC, Morse MA, Clough RW, Czito BG (2009) Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 73:148–153

    Article  PubMed  CAS  Google Scholar 

  13. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, Nakashima A, Sueda T (2009) Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 250(6):950–956

    Article  PubMed  Google Scholar 

  14. Eng C, Ramanathan RK, Wong MK, Remick SC, Dai L, Wade-Oliver KT, Mani S, Kindler HL (2004) A phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol 27:565–569

    Article  PubMed  CAS  Google Scholar 

  15. Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical traials. Br J Cancer 96:896–902

    Article  PubMed  CAS  Google Scholar 

  16. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C, GERCOR Group (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15:1339–1343

    Article  PubMed  CAS  Google Scholar 

  17. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332–2338

    Article  PubMed  CAS  Google Scholar 

  18. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K, ACTS-GC Group (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820

    Article  PubMed  CAS  Google Scholar 

  19. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu Ohtsu, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase 3 study. Lancet Oncol 10:1063–1069

    Article  PubMed  CAS  Google Scholar 

  20. Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E (2009) A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 63:313–319

    Article  PubMed  CAS  Google Scholar 

  21. Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62:849–855

    Article  PubMed  CAS  Google Scholar 

  22. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2004) Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91:1769–1774

    Article  PubMed  CAS  Google Scholar 

  23. Valle JW, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281

    Article  PubMed  CAS  Google Scholar 

  24. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103:469–474

    Article  PubMed  CAS  Google Scholar 

  25. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H (2006) Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94:1575–1579

    PubMed  CAS  Google Scholar 

  26. Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Toda N, Tada M, Kawabe T, Omata M (2009) A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer. Oncology 77(5):300–303

    Article  PubMed  CAS  Google Scholar 

  27. Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O, Toda N, Yasuda I, Hasebe O, Maetani I, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M (2010) Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmarcol 65:1101–1107

    Article  CAS  Google Scholar 

  28. Kanai M, Yoshimura K, Tsumura T, Asada M, Suzuki C, Niimi M, Matsumoto S, Nishimura T, Nitta T, Yasuchika K, Taura K, Mori Y, Hamada A, Inoue N, Tada S, Yanagihara K, Yazumi S, Osaki Y, Chiba T, Ikai I, Fukushima M, Uemoto S, Hatano E (2011) A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmarcol 67:1429–1434

    Article  CAS  Google Scholar 

  29. Takashima A, Morizane C, Ishii H, Nakamura K, Fukuda H, Okusaka T, Furuse J (2010) Randomized phase II study of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805). Jpn J Clin Oncol 40:1189–1191

    Article  PubMed  Google Scholar 

  30. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, Nakashima A, Sueda T (2009) Gemcitabine-based adjuvant chemotherapy improved survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg 13:1470–1479

    Article  PubMed  Google Scholar 

  31. Ren Q, Kao V, Grem JL (1998) Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 4:2811–2818

    PubMed  CAS  Google Scholar 

  32. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA III, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347–353

    Article  PubMed  CAS  Google Scholar 

  33. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmocol 38:567–572

    CAS  Google Scholar 

  34. Madajewicz S, Hentschel P, Burns P, Caruso R, Fiore J, Fried M, Malhotra H, Ostrow S, Sugarman S, Viola M (2000) Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. J Clin Oncol 18:3553–3557

    PubMed  CAS  Google Scholar 

  35. Pressacco J, Mirovski B, Erlichman C, Hedley DW (1995) Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res 55:1505–1508

    PubMed  CAS  Google Scholar 

  36. Nakahira S, Nakamori S, Tsujie M, Takeda S, Sugimoto K, Takahashi Y, Okami J, Marubashi S, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M (2008) Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Anticancer Res 28:179–186

    PubMed  CAS  Google Scholar 

  37. Floyd FJ, Hornbeck CL, Byfield JE, Griffiths JC, Frankel SS (1982) Clearance of continuously infused 5-fluoraouracil in adults having lung or gastrointestinal carcinoma with or without hepatic metastases. Drug Intell Clin Pharm 16:665–667

    PubMed  CAS  Google Scholar 

  38. Yoon DH, Lee HJ, Hong YS, Kim K, Lee SS, Lee JL, Chang HM, Ryu MH, Kang YK, Lee JS, Kim TW (2011) A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer with or without hepatic dysfunction. Invest New Drugs 29:332–339

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, Iwate, 020-8505, Japan

    Takeshi Takahara, Hiroyuki Nitta, Yasushi Hasegawa, Naoko Itou, Masahiro Takahashi, Satoshi Nishizuka & Go Wakabayashi

Authors
  1. Takeshi Takahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroyuki Nitta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasushi Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoko Itou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masahiro Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Satoshi Nishizuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Go Wakabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeshi Takahara.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Takahara, T., Nitta, H., Hasegawa, Y. et al. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures. Cancer Chemother Pharmacol 69, 1127–1133 (2012). https://doi.org/10.1007/s00280-011-1805-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-011-1805-7

Keywords

Search

Navigation